Victory Capital Management Inc. Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Victory Capital Management Inc. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 171,037 shares of the medical research company’s stock after acquiring an additional 911 shares during the period. Victory Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $85,108,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of TMO. Bridgewater Advisors Inc. acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $1,100,000. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Thermo Fisher Scientific by 4.4% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 7,339 shares of the medical research company’s stock worth $3,652,000 after buying an additional 312 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Thermo Fisher Scientific by 34.1% during the 1st quarter. Larson Financial Group LLC now owns 7,257 shares of the medical research company’s stock valued at $3,611,000 after purchasing an additional 1,845 shares during the last quarter. First Business Financial Services Inc. boosted its position in shares of Thermo Fisher Scientific by 8.6% during the 1st quarter. First Business Financial Services Inc. now owns 2,887 shares of the medical research company’s stock valued at $1,437,000 after acquiring an additional 228 shares during the last quarter. Finally, West Family Investments Inc. increased its stake in Thermo Fisher Scientific by 83.3% in the 1st quarter. West Family Investments Inc. now owns 900 shares of the medical research company’s stock worth $448,000 after purchasing an additional 409 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Up 2.2%

NYSE:TMO opened at $425.28 on Friday. The firm has a fifty day simple moving average of $410.13 and a 200-day simple moving average of $473.73. The company has a market capitalization of $160.54 billion, a P/E ratio of 24.94, a PEG ratio of 2.21 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter in the previous year, the business posted $5.11 earnings per share. The firm’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TMO shares. Royal Bank Of Canada cut their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a report on Friday, July 11th. Barclays decreased their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Tuesday, June 24th. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, April 24th. Finally, UBS Group downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and cut their price objective for the company from $500.00 to $460.00 in a report on Tuesday, July 8th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $600.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.